Evidence creation for myelofibrosis: Challenges and opportunities.
Br J Haematol
; 204(1): 19-21, 2024 01.
Article
en En
| MEDLINE
| ID: mdl-38083995
ABSTRACT
Evidence-based guidelines for rare diseases, such as myelofibrosis (MF), continue to prove challenging to develop, and decision-making for MF is complex. The British Society for Haematology (BSH) has created a pragmatic symptom-guided risk-adapted framework on all aspects of management of MF and shared best practices on the use of JAK inhibitors, transplantation and other conventional therapies in the management of myelofibrosis. Commentary on McLornan et al. The management of myelofibrosis A British Society for Haematology Guideline. Br J Haematol 2024;204136-150.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Trasplante de Células Madre Hematopoyéticas
/
Mielofibrosis Primaria
/
Inhibidores de las Cinasas Janus
Límite:
Humans
Idioma:
En
Revista:
Br J Haematol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Canadá